PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology

Machado, Caio Bezerra; Silva, Emerson Lucena da; Nogueira, Beatriz Maria Dias; Filho, Manoel Odorico de Moraes; Montenegro, Raquel Carvalho; Moraes, Maria Elisabete Amaral de; Moreira-Nunes, Caroline Aquino

doi:10.21873/anticanres.15014

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poly (ADP-ribose) polymerase 1 (PARP1) is an enzyme that functions in DNA damage, repair, transcription, and, through regulation of cellular mitosis and processes such as apoptosis and necrosis, alters the life cycle of cancer cells [50,51]. PARP1 overexpression and PARP1 inhibitors as possible therapies have been reported in numerous cancers [52,53], putting forward PARP1 as a potential biomarker implicated in the development of pSS. Lymphotoxin-β (LTβ) is a type II membrane protein of the TNF family.…”

Section: Discussionmentioning

confidence: 99%

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma

Mohammadnezhad

Azgomi

Manna

et al. 2023

IJMS

View full text Add to dashboard Cite

Primary Sjogren syndrome (pSS) is the second most common autoimmune disorder worldwide, which, in the worst scenario, progresses to Non-Hodgkin Lymphoma (NHL). Despite extensive studies, there is still a lack of knowledge about developing pSS for NHL. This study focused on cells’ signaling in pSS progression to the NHL type of diffuse large B-cell lymphoma (DLBCL). Using bulk RNA and single cell analysis, we found five novel pathologic-independent clusters in DLBCL based on cells’ signaling. B-cell receptor (BCR) signaling was identified as the only enriched signal in DLBCL and pSS peripheral naive B-cells or salivary gland-infiltrated cells. The evaluation of the genes in association with BCR has revealed that targeting CD79A, CD79B, and LAMTOR4 as the shared genes can provide novel biomarkers for pSS progression into lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma

Mohammadnezhad

Azgomi

Manna

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Our research also showed that XIST might be regulated by gene mutation (including APC, BRCA1, BRCA2, TP53 and PIK3CA) in several cancers, especially BRCA, PRAD and READ. Mutations of these genes modulate expressions of diverse downstream genes and have become important therapeutic targets for anticancer drug development [ 57 , 58 ]. For instance, PARP inhibitors have been used for cancer patients with BRCA1/BRCA2 mutation.…”

Section: Discussionmentioning

confidence: 99%

Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers

Han

Shi

et al. 2022

Heliyon

View full text Add to dashboard Cite

Prognostic Roles of LncRNA XIST and Its Potential Mechanisms in Human Cancers: A Pan-Cancer Analysis

Wang

Shi

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: X-inactive specific transcript (XIST), it has been found, is abnormal expression in various neoplasms. This work aims to explore its potential molecular mechanisms and prognostic roles in types of malignancies. Methods: This research comprehensively investigated XIST transcription across cancers from Oncomine, TIMER 2.0 and GEPIA2. Correlations of XIST expression with prognosis, miRNAs, interacting protens, immune infiltrates, checkpoint markers and mutations of tumor-associated genes were also analyzed by public databases. Results: Compared to normal tissues, XIST was lower in BRCA, COAD, LUAD, lymphoma and OV in Oncomine; In TIMER 2.0, XIST was decreased in BRCA, KICH, THCA and UCEC, but increased in KIRC and PRAD; In GEPIA2, XIST was down-regulated in CESC, COAD, OV, READ, STAD, UCEC and UCS. Public databases also showed that XIST was a good indicator of prognosis in BRCA, CESC, COAD, STAD, OV and so on, but a bad one in KIRC, KIRP and so on. From starBase, we found 29 proteins interacting with XIST, and identified 4 miRNAs, including miR-103a-3p, miR-107, miR-130b-3p and miR-96-5p, which might be sponged by XIST in cancers. Furthermore, XIST was linked with immune infiltration, especially T cell CD4+, and was related to over 20 immune checkpoint markers. In addition, XIST was associated with several tumor-associated gene mutations in some cancers. Conclusion: In summary, abnormal expression of XIST influenced prognosis, miRNAs, immune cell infiltration and mutations of tumor-associated genes across cancers, especially BRCA and colorectal cancer. More efforts should be made to detect potential molecular mechanisms of XIST in the carcinogenesis.

show abstract

PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology

Cited by 3 publications

References 0 publications

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma

Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers

Prognostic Roles of LncRNA XIST and Its Potential Mechanisms in Human Cancers: A Pan-Cancer Analysis

Contact Info

Product

Resources

About